4.31
-0.4(-8.49%)
Currency In USD
| Previous Close | 4.71 |
| Open | 4.69 |
| Day High | 4.93 |
| Day Low | 4.28 |
| 52-Week High | 13.53 |
| 52-Week Low | 3.18 |
| Volume | 532,833 |
| Average Volume | 684,075 |
| Market Cap | 234.5M |
| PE | -0.42 |
| EPS | -10.38 |
| Moving Average 50 Days | 5.43 |
| Moving Average 200 Days | 9.14 |
| Change | -0.4 |
If you invested $1000 in Alumis Inc. Common Stock (ALMS) since IPO date, it would be worth $324.06 as of April 25, 2025 at a share price of $4.31. Whereas If you bought $1000 worth of Alumis Inc. Common Stock (ALMS) shares 0 years ago, it would be worth $324.06 as of April 25, 2025 at a share price of $4.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire Inc.
Apr 21, 2025 10:30 AM GMT
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
GlobeNewswire Inc.
Apr 04, 2025 8:34 PM GMT
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO,
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
GlobeNewswire Inc.
Mar 25, 2025 6:30 AM GMT
- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial